If you suspect ATTR amyloidosis, it is important to refer your patients to the National Amyloidosis Centre (NAC) to be assessed
Requirements for clinical referral to the National Amyloidosis Centre (NAC)1
Part of University College London Centre for Amyloidosis and Acute Phase Proteins in the UK, the NHS NAC is the current referral centre for all patients with amyloidosis, providing specialist care and research nationally. It is commissioned by NHS National Specialised Services and funded by the Department of Health2–4
The clinical service is delivered by a multidisciplinary team of specialists in rheumatology, immunology, nephrology, neurology and cardiology, making it the world’s largest and most diverse practice2–4
Evidence of suggestive symptoms and inflammation:
Significantly elevated CRP, SAA, WBC, or ESR with symptoms
Family history
Suggestive symptoms with a family history of autoinflammatory disease or AA amyloidosis persistent inflammation
Full details of
- Previous imaging and reports
- Biopsies with reports
- Treatment history (medications, dates, outcomes)
- Blood work (autoantibodies, haematology, infectious workup)
A second opinion on patients with
Suspected recurrent idiopathic pericarditis
- Fulfilment of ESC criteria, including imaging reports, evidence of initiating prophylactic colchicine treatment, and are already receiving ongoing care from a cardiology/rheumatology unit
Suspected adult-onset Still’s disease
- Fulfilment of classification criteria, including imaging and serology reports, a full treatment history, and are already receiving ongoing care from a rheumatology unit
Care coordination
- Full details of all teams involved in current care
- Referred patients must remain under the care of the referring team
- Patients without ongoing local care arrangements cannot be accepted for national specialist services review
For further information for referring HCPs, please visit
https://www.ucl.ac.uk/amyloidosis/national-amyloidosis-centre/information-referring-physicians
To support earlier diagnosis and treatment of ATTR amyloidosis, enhancing healthcare capability through improved awareness, diagnostic infrastructure, and clear referral pathways is essential5,6
The UK Amyloidosis Network (UKAN) is expanding access to specialist services through new regional centres in Liverpool and Birmingham. These centres will work in close collaboration with the NAC to provide more localised diagnostic services and multidisciplinary expertise.
The development of UKAN spoke centres aims to:
Reduce travel burden
Enabling patients to access specialist care closer to home
Streamline the diagnostic pathway
Supporting earlier identification and referral
Expand access to specialist diagnostics
Ensuring more patients with suspected ATTR amyloidosis are evaluated appropriately
It is important to suspect ATTR amyloidosis signs and symptoms to facilitate earlier diagnosis and treatment7
Early intervention for ATTR amyloidosis may improve quality of life7–14
GB-69506 | November 2025
